Nov. 15, 2017 (GLOBE NEWSWIRE) — BioCancell Therapeutics (TASE:BICL), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies to treat cancer, announced today additional final clinical trial results for its combination therapy clinical trial of BC-819, BioCanCell’s lead drug, together with BCG, a current therapy for bladder cancer patients (the “Combination Therapy”). BC-819 is an intravesical gene therapy consisting of a recombinant DNA construct which delivers a lethal cellular toxin, engineered from diphtheria, specifically to malignant cells in the bladder. Full data has been submitted to the 2018 Genitourinary Cancers Symposium Annual meeting being held in San Francisco, CA from February 8th through 10th, 2018.

For more information, see:  BioSpace.com https://www.biospace.com/article/releases/biocancell-announces-updated-results-from-the-phase-ii-clinical-trial-of-bc-819-and-bcg-in-patients-with-bladder-cancer/?keywords=Biocancell